Alnylam Initiates ENVISION Phase 3 Clinical Study with Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)
CAMBRIDGE, Mass.--(BUSINESS WIRE) November 7, 2017 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the initiation of the ENVISION Phase 3 clinical study with givosiran, a subcutaneously... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 7, 2017 Category: Pharmaceuticals Source Type: clinical trials
FDA Grants Breakthrough Therapy Designation for Alnylam's Givosiran for the Prophylaxis of Attacks in Patients with Acute Hepatic Porphyria
CAMBRIDGE, Mass.--(BUSINESS WIRE) May 31, 2017 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has received Breakthrough Therapy designation from the U.S. Food and Drug Administration... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 31, 2017 Category: Pharmaceuticals Source Type: clinical trials
Harvoni Treatment Porphyria Cutanea Tarda
Conditions: Porphyria Cutanea Tarda; Hepatitis C Intervention: Drug: Harvoni Sponsors: Wake Forest University Health Sciences; Gilead Sciences; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institutes of Health (NIH) Not yet recruiting - verified April 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 13, 2017 Category: Research Source Type: clinical trials
Harvoni Treatment Porphyria Cutanea Tarda
Conditions: Porphyria Cutanea Tarda; Hepatitis C Intervention: Drug: Harvoni Sponsors: Herbert L. Bonkovsky, MD; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Gilead Sciences Not yet recruiting - verified April 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 13, 2017 Category: Research Source Type: clinical trials
Harvoni Treatment Porphyria Cutanea Tarda
Conditions: Porphyria Cutanea Tarda; Hepatitis C Intervention: Drug: Harvoni Sponsors: Wake Forest University Health Sciences; Gilead Sciences; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institutes of Health (NIH) Not yet recruiting - verified April 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 13, 2017 Category: Research Source Type: clinical trials
A Study to Evaluate Long-term Safety and Clinical Activity of ALN-AS1 in Patient With Acute Intermittent Porphyria (AIP)
Condition: Acute Intermittent Porphyria Intervention: Drug: ALN-AS1 Sponsor: Alnylam Pharmaceuticals Enrolling by invitation - verified October 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 28, 2016 Category: Research Source Type: clinical trials
